دواعي استعمال تريسيبا 100وحدة دولية/مل فليكستاتش قلم معبأ للحقن

Tresiba 100 units/ml FlexTouch pre-filled pen containing insulin degludec, an ultra-long-acting basal insulin by Novo Nordisk.

• To improve glycemic control in patients 1 year of age and older with diabetes mellitusالفئة: Adults and children >=1 yearDailyMed (U.S. National Library of Medicine)

• Hypoglycemia, allergic reactions, injection-site reactions, lipodystrophy/localized cutaneous amyloidosis, pruritus, rash, edema, weight gain; nasopharyngitis, URTI, headache in trials.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)

• During episodes of hypoglycemia; hypersensitivity to insulin degludec or excipients.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)

• Never share a pen between patients, even if the needle is changed.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)
• Hyperglycemia or hypoglycemia with changes in insulin regimen; make changes under medical supervision.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)
• Hypoglycemia is the most common adverse reaction and may be life-threatening.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)
• Medication errors from accidental mix-ups between insulin products; check the label before each injection.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)
• Severe, life-threatening generalized allergy including anaphylaxis.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)
• Hypokalemia.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)
• Fluid retention and heart failure with concomitant thiazolidinediones.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)

• Antidiabetic agents, ACE inhibitors, ARBs, disopyramide, fibrates, fluoxetine, MAO inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogues (e.g. octreotide), sulfonamide antibiotics, GLP-1 agonists, DPP-4 and SGLT-2 inhibitorsMay increase risk of hypoglycemia; dose reduction and glucose monitoring may be needed.DailyMed (U.S. National Library of Medicine)
• Atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetics, thyroid hormonesMay decrease the blood-glucose-lowering effect; dose increase may be needed.DailyMed (U.S. National Library of Medicine)
• Alcohol, beta-blockers, clonidine, lithium salts, pentamidineMay increase or decrease the glucose-lowering effect.DailyMed (U.S. National Library of Medicine)
• Beta-blockers, clonidine, guanethidine, reserpineSigns of hypoglycemia may be reduced or absent.DailyMed (U.S. National Library of Medicine)

• Available data from a randomized trial in pregnant women with type 1 diabetes and observational data have not identified a drug-associated risk of major birth defects or miscarriage; poorly controlled diabetes carries maternal and fetal risks.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk or effects on breastfed infants; insulin degludec is present in rat milk.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)

• Blood glucose and HbA1c; potassium in patients at risk of hypokalemia; signs of fluid retention with thiazolidinediones.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)